Blockchain Registration Transaction Record

Tonix Pharmaceuticals Appoints Joseph Hand, Esq., as General Counsel and EVP of Operations; Preparing for Potential Launch of TNX-102 SL for Fibromyalgia

Tonix Pharmaceuticals appoints Joseph Hand, Esq., as General Counsel and EVP of Operations, signaling potential FDA approval for TNX-102 SL. Collaborations with the U.S. Department of Defense highlight Tonix's commitment to healthcare innovation and addressing medical needs in high-risk settings.

This news highlights the strategic appointment of Joseph Hand, Esq., at Tonix Pharmaceuticals and the company's focus on developing innovative therapies for pain management and public health challenges. With a potential FDA approval on the horizon for TNX-102 SL for fibromyalgia, Tonix is at the forefront of advancing treatments for chronic conditions. Additionally, the collaboration with the U.S. Department of Defense underscores Tonix's commitment to addressing critical medical needs in high-risk environments, showcasing its diverse portfolio and dedication to healthcare advancements.